Financial Snapshot

Revenue
$2.162M
TTM
Gross Margin
-51.13%
TTM
Net Earnings
-$532.3M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
957.03%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$502.7M
Q3 2024
Cash
Q3 2024
P/E
-1.744
Nov 29, 2024 EST
Free Cash Flow
-$99.33M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $28.53M $31.82M $24.28M $10.95M $6.990M $382.0K
YoY Change -10.33% 31.04% 121.74% 56.65% 1729.84%
% of Gross Profit
Research & Development $71.29M $87.82M $69.04M $32.60M $25.11M $362.0K
YoY Change -18.82% 27.2% 111.75% 29.84% 6836.46%
% of Gross Profit
Depreciation & Amortization $222.0K $199.0K $184.0K $100.0K $13.00K
YoY Change 11.56% 8.15% 84.0% 669.23%
% of Gross Profit
Operating Expenses $99.82M $119.7M $93.32M $43.55M $32.10M $744.0K
YoY Change -16.63% 28.31% 114.27% 35.67% 4214.52%
Operating Profit -$99.82M -$119.7M -$93.32M -$43.55M
YoY Change -16.63% 28.31% 114.27%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $24.47M $6.220M $2.883M $2.160M -$1.320M
YoY Change 293.44% 115.75% 33.47% -263.64%
% of Operating Profit
Other Income/Expense, Net $24.02M $15.54M $6.470M $1.892M -$140.0K
YoY Change 54.62% 140.11% 241.97% -1451.43%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$75.80M -$104.2M -$86.85M -$41.66M -$33.55M -$744.0K
YoY Change -27.25% 19.98% 108.47% 24.17% 4409.41%
Income Tax $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$75.80M -$104.2M -$86.85M -$41.66M -$33.55M -$744.0K
YoY Change -27.25% 19.98% 108.47% 24.17% 4409.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.35 -$0.48 -$0.44
Diluted Earnings Per Share -$0.35 -$0.48 -$438.9K -$100.9K -$0.15 -$3.418K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $611.2M $661.0M $765.4M $215.8M $118.9M $138.0K
YoY Change -7.53% -13.64% 254.68% 81.54% 86037.68%
Cash & Equivalents $42.65M $101.1M $132.4M $29.80M $3.469M $138.0K
Short-Term Investments $568.6M $559.9M $633.0M $186.0M $115.4M
Other Short-Term Assets $1.519M $3.819M $3.642M $3.800M $187.0K $20.00K
YoY Change -60.23% 4.86% -4.16% 1932.09% 835.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $616.4M $667.3M $772.1M $220.7M $119.9M $158.0K
YoY Change -7.63% -13.57% 249.83% 84.09% 75776.58%
Property, Plant & Equipment $4.322M $4.685M $3.657M $700.0K $646.0K $0.00
YoY Change -7.75% 28.11% 422.43% 8.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $141.0K $138.0K $421.0K $400.0K $421.0K $0.00
YoY Change 2.17% -67.22% 5.25% -4.99%
Other Assets $587.0K
YoY Change
Total Long-Term Assets $5.050M $4.823M $4.078M $1.100M $1.067M $0.00
YoY Change 4.71% 18.27% 270.73% 3.09%
Total Assets $621.5M $672.1M $776.2M $221.8M $121.0M $158.0K
YoY Change
Accounts Payable $2.209M $2.139M $3.925M $2.200M $2.030M $83.00K
YoY Change 3.27% -45.5% 78.41% 8.37% 2345.78%
Accrued Expenses $11.77M $11.02M $13.00M $4.400M $1.163M $219.0K
YoY Change 6.74% -15.22% 195.45% 278.33% 431.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $600.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.97M $13.16M $16.93M $6.600M $3.204M $902.0K
YoY Change 6.18% -22.24% 156.44% 105.99% 255.21%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.388M $3.904M $13.23M $200.0K
YoY Change -38.83% -70.49% 6514.5%
Total Long-Term Liabilities $2.388M $3.904M $13.23M $200.0K $0.00 $0.00
YoY Change -38.83% -70.49% 6514.5%
Total Liabilities $16.36M $17.07M $30.15M $6.700M $3.204M $902.0K
YoY Change -4.12% -43.41% 350.06% 109.11% 255.21%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 218.9K 216.7K 197.9K
Diluted Shares Outstanding 218.9K 216.7K 197.9K
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $928.31 Million

About Nuvation Bio Inc.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 203 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The firm is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. The company is conducting Phase I/II study of NUV-1511.

Industry: Pharmaceutical Preparations Peers: Atea Pharmaceuticals, Inc. Cara Therapeutics, Inc. Edgewise Therapeutics, Inc. Esperion Therapeutics, Inc. Evolus, Inc. JOHNSON & JOHNSON PHIBRO ANIMAL HEALTH CORP Rani Therapeutics Holdings, Inc. Tarsus Pharmaceuticals, Inc. Tricida, Inc.